APAC Veterinary Pain Management Market - Industry Trends and Forecast to 2031
Asia-Pacific veterinary pain management market is expected to reach USD 586,635.95 thousand by 2030 from USD 409,355.09 thousand in 2022 growing at a CAGR of 4.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market SegmentationAsia Pacific Veterinary Pain Management Market, By Product Type (Analgesics, Corticosteroids, and Alpha 2 Agonists), Drug Type (Branded and Generic), Mode of Purchase (Prescription Based and OTC), Animal Type (Companion Animal and Production Animal), Pain Source (Chronic Pain, Acute Pain, Post-Operative Pain, and Dental Pain), Dosage (Solid, Liquid, and Semi-Solid), Route of Administration (Parenteral, Oral, and Topical), End User (Veterinary Hospitals, Veterinary Clinics, Pet Shops, Animal Farms, Academic & Research Institutes, and Others), Country (China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Taiwan, Vietnam, and rest of Asia-Pacific) – Industry Trends and Forecast to 2030
Overview of Asia Pacific Veterinary Pain Management Market Dynamics
Driver
• Rising incidences of pet diseases
Restraint
• High costs of pet care
Opportunity
• Technological advancements for pain management
Market PlayersSome of the major market players operating in the Asia-Pacific veterinary pain management market are:• Dechra Pharmaceuticals PLC
• Virbac
• Norbrook
• Bimeda, Inc.
• Inovet ( A subsidiary of Orion Group)
• Chanelle Pharma
• Vetoquinol
• Elanco
• Merck & Co., Inc.
• Ceva Animal Health, LLC
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.